The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators. These findings are likely to change the recommendations for treatment of indolent forms of lymphoma.
...
- ‹ previous
- 104 of 128
- next ›